PubMed
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Winbanks et al., 2009
Healing & RecoveryResearch Only — Extreme CautionS
Follistatin 344
FST344 / Myostatin Inhibitor
Follistatin 344 is an isoform of follistatin (FST), a naturally occurring glycoprotein that binds and neutralizes TGF-β superfamily members, most notably myostatin (GDF-8) and activin A. Animal studies show dramatic and permanent muscle hypertrophy with single gene therapy doses. Human pharmacokinetic and safety data are extremely limited; the risk of irreversible muscular hypertrophy and unknown off-target effects make this highly experimental. Research only — extreme caution advised.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- S
- Community score
- 175
- Trackers
- 3,543
Trend index
Overview
About Follistatin 344
Follistatin 344 is an isoform of follistatin (FST), a naturally occurring glycoprotein that binds and neutralizes TGF-β superfamily members, most notably myostatin (GDF-8) and activin A. Animal studies show dramatic and permanent muscle hypertrophy with single gene therapy doses. Human pharmacokinetic and safety data are extremely limited; the risk of irreversible muscular hypertrophy and unknown off-target effects make this highly experimental. Research only — extreme caution advised.
- Category
- Healing & Recovery
- Regulatory status
- Research Only — Extreme Caution
- Also known as
- FST344 / Myostatin Inhibitor
- Self-reports
- 6
Community
What 6 users report
6 community reports
Positive 100% · Neutral 0% · Negative 0%
Most reported benefits
Recovery
6
Sleep
6
Energy
3
Dose distribution
Median: 50–100 mcg · Most common: 50–100 mcg
0–25
0
25–50
0
50–100
4
100–200
2
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
0
Commonly stacked with
Research
Cited research (2)
Source
ClinicalTrials.gov
Follistatin / Myostatin inhibition studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
Help
Frequently asked
What do PeptIQ users report about Follistatin 344?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Follistatin 344, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for Follistatin 344?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Follistatin 344 safe to use?
This wiki does not assess safety or recommend use. Follistatin 344 is listed as Research Only — Extreme Caution. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Follistatin 344?
Research, primarily in animal models, suggests Follistatin 344 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Follistatin 344?
Follistatin 344 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Follistatin 344 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Follistatin 344?
The safety and effectiveness of Follistatin 344 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Follistatin 344?
While there are over 200 published studies on Follistatin 344, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source